Phase 3 Readout~month

Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy,

Name: Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy,
Start: 2029-12-01

December 1, 2029

Company: Neurogene Inc. (NGNE)
Drug: rett
Indication: Rett Syndrome

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Baseline-Controlled, Open-Label, Multicenter, Single-Arm, Pivotal Study to Evaluate the Efficacy, — NGNE Phase 3 Readout | BioSniper